Literature DB >> 3838315

The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation.

K A Parker, D M Tollefsen.   

Abstract

125I-labeled heparin cofactor II (HCII) was mixed with plasma and coagulation was initiated by addition of CaCl2, phospholipids, and kaolin or tissue factor. In the presence of 67 micrograms/ml of dermatan sulfate, radioactivity was detected in a band which corresponded to the thrombin-HCII complex (Mr = 96,000) upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis. No other complexes were observed. The thrombin-HCII complex was undetectable when 5 units/ml of heparin was present or when prothrombin-deficient plasma was used. In experiments with purified proteases, HCII did not significantly inhibit coagulation factors VIIa, IXa, Xa, XIa, XIIa, kallikrein, activated protein C, plasmin, urokinase, tissue plasminogen activator, leukocyte elastase, the gamma-subunit of nerve growth factor, and the epidermal growth factor-binding protein. HCII inhibited leukocyte cathepsin G slowly, with a rate constant of 8 X 10(4) M-1 min-1 in the presence of dermatan sulfate. These results indicate that the protease specificity of HCII is more restricted than that of other plasma protease inhibitors and suggest that the anticoagulant effect of dermatan sulfate is due solely to inhibition of thrombin by HCII.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3838315

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin.

Authors:  B Bray; D A Lane; J M Freyssinet; G Pejler; U Lindahl
Journal:  Biochem J       Date:  1989-08-15       Impact factor: 3.857

Review 2.  The endothelial glycocalyx: composition, functions, and visualization.

Authors:  Sietze Reitsma; Dick W Slaaf; Hans Vink; Marc A M J van Zandvoort; Mirjam G A oude Egbrink
Journal:  Pflugers Arch       Date:  2007-01-26       Impact factor: 3.657

3.  Inhibition of chymotrypsin by heparin cofactor II.

Authors:  F C Church; C M Noyes; M J Griffith
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

Review 4.  Glycosaminoglycans and the regulation of blood coagulation.

Authors:  M C Bourin; U Lindahl
Journal:  Biochem J       Date:  1993-01-15       Impact factor: 3.857

5.  Coagulation protein function: enhancement of the anticoagulant effect of acetaldehyde by sulfated glycosaminoglycans.

Authors:  A S Brecher; M T Adamu
Journal:  Dig Dis Sci       Date:  2001-09       Impact factor: 3.199

Review 6.  Modeling thrombin generation: plasma composition based approach.

Authors:  Kathleen E Brummel-Ziedins; Stephen J Everse; Kenneth G Mann; Thomas Orfeo
Journal:  J Thromb Thrombolysis       Date:  2014-01       Impact factor: 2.300

7.  Heparin cofactor II, a serine protease inhibitor, promotes angiogenesis via activation of the AMP-activated protein kinase-endothelial nitric-oxide synthase signaling pathway.

Authors:  Yasumasa Ikeda; Ken-ichi Aihara; Sumiko Yoshida; Takashi Iwase; Soichiro Tajima; Yuki Izawa-Ishizawa; Yoshitaka Kihira; Keisuke Ishizawa; Shuhei Tomita; Koichiro Tsuchiya; Masataka Sata; Masashi Akaike; Shigeaki Kato; Toshio Matsumoto; Toshiaki Tamaki
Journal:  J Biol Chem       Date:  2012-08-17       Impact factor: 5.157

8.  Non-enzymatic glycation reduces heparin cofactor II anti-thrombin activity.

Authors:  A Ceriello; E Marchi; M Barbanti; M R Milani; D Giugliano; A Quatraro; P Lefebvre
Journal:  Diabetologia       Date:  1990-04       Impact factor: 10.122

9.  Interaction of thrombin with antithrombin, heparin cofactor II, and protein C inhibitor.

Authors:  H C Whinna; F C Church
Journal:  J Protein Chem       Date:  1993-12

Review 10.  Polarized Proteins in Endothelium and Their Contribution to Function.

Authors:  Abigail G Wolpe; Claire A Ruddiman; Phillip J Hall; Brant E Isakson
Journal:  J Vasc Res       Date:  2021-01-27       Impact factor: 1.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.